Letters
Shared scheme for assessing drugs for multiple sclerosis: Cost effective provision of effective treatments for multiple sclerosis
BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7400.1212 (Published 29 May 2003) Cite this as: BMJ 2003;326:1212
- Jacqueline C Napier, associate medical director (jnapier@schering.co.uk),
- Richard Francis, country manager United Kingdom and Ireland,
- Glyn Wright, general manager
- Schering Health Care, Burgess Hill, West Sussex RH15 9NE
- Biogen, Maidenhead, Berkshire SL6 3UD
- Teva Pharmaceuticals, High Wycombe, Buckinghamshire HP13 7SS
EDITOR—Sudlow and Counsell think that the UK government's risk sharing scheme for the provision of disease modifying drugs for multiple sclerosis (interferon beta and glatiramer acetate) may be flawed.1
Firstly, the risk sharing scheme was introduced to ensure that the disease modifying drugs in question are acquired by the NHS in a cost effective manner, which will be reviewed by the …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.